Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: AST-OPC1
Eligibility
Major Inclusion Criteria:
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
scan, with sufficient visualization of the spinal cord injury epicenter and lesion
margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must
be provided and documented (i.e., signed informed consent forms) no later than 37 days
following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days
following SCI
Major Exclusion Criteria:
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior
surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or
validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity
of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk
for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) > 35 or weight > 300 lbs.
- Active participation in another experimental procedure/intervention
Ages Eligible for Study
18 Years - 69 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Cutler
408-885-2100
I'm interested
Psoriasis Clinical Trials
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: AST-OPC1
Eligibility
Major Inclusion Criteria:
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
scan, with sufficient visualization of the spinal cord injury epicenter and lesion
margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must
be provided and documented (i.e., signed informed consent forms) no later than 37 days
following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days
following SCI
Major Exclusion Criteria:
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior
surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or
validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity
of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk
for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) > 35 or weight > 300 lbs.
- Active participation in another experimental procedure/intervention
Ages Eligible for Study
18 Years - 69 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Cutler
408-885-2100
I'm interested
Dermatology Clinical Trials
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: AST-OPC1
Eligibility
Major Inclusion Criteria:
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
scan, with sufficient visualization of the spinal cord injury epicenter and lesion
margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must
be provided and documented (i.e., signed informed consent forms) no later than 37 days
following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days
following SCI
Major Exclusion Criteria:
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior
surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or
validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity
of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk
for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) > 35 or weight > 300 lbs.
- Active participation in another experimental procedure/intervention
Ages Eligible for Study
18 Years - 69 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Cutler
408-885-2100
I'm interested
Pediatric Dermatology Clinical Trials
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: AST-OPC1
Eligibility
Major Inclusion Criteria:
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
scan, with sufficient visualization of the spinal cord injury epicenter and lesion
margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must
be provided and documented (i.e., signed informed consent forms) no later than 37 days
following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days
following SCI
Major Exclusion Criteria:
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior
surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or
validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity
of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk
for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) > 35 or weight > 300 lbs.
- Active participation in another experimental procedure/intervention
Ages Eligible for Study
18 Years - 69 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Cutler
408-885-2100
I'm interested
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: AST-OPC1
Eligibility
Major Inclusion Criteria:
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
scan, with sufficient visualization of the spinal cord injury epicenter and lesion
margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must
be provided and documented (i.e., signed informed consent forms) no later than 37 days
following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days
following SCI
Major Exclusion Criteria:
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior
surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or
validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity
of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk
for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) > 35 or weight > 300 lbs.
- Active participation in another experimental procedure/intervention
Ages Eligible for Study
18 Years - 69 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Cutler
408-885-2100
I'm interested
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: AST-OPC1
Eligibility
Major Inclusion Criteria:
- Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
- Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
- Last fully preserved single neurological level (SNL) from C-4 to C-7
- From 18 through 69 years of age at time of injury
- Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI)
scan, with sufficient visualization of the spinal cord injury epicenter and lesion
margins to enable post-injection safety monitoring
- Informed consent for this protocol and the companion long term follow-up protocol must
be provided and documented (i.e., signed informed consent forms) no later than 37 days
following injury
- Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days
following SCI
Major Exclusion Criteria:
- SCI due to penetrating trauma
- Traumatic anatomical transection or laceration of the spinal cord based on prior
surgery or MRI
- Any concomitant injury that interferes with the performance, interpretation or
validity of neurological examinations
- Inability to communicate effectively with neurological examiner such that the validity
of patient data could be compromised
- Significant organ damage or systemic disease that would create an unacceptable risk
for surgery or immunosuppression
- History of any malignancy (except non-melanoma skin cancers)
- Pregnant or nursing women
- Body mass index (BMI) > 35 or weight > 300 lbs.
- Active participation in another experimental procedure/intervention
Ages Eligible for Study
18 Years - 69 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Cutler
408-885-2100
I'm interested